semaglutide news oct 26 2025 Are you eligible? Medicare's new GLP-1 Bridge program will cover certain weight-loss drugs starting this week. But as of now, the program isn't permanent: http://www.wkyc.com/article/news/nation-world/medicare-covering-glp-1-weight-loss-drugs-bridge How Ozempic Maker Novo Nordisk

The maker of Wegovy is threatening to sue and take regulatory action, saying Hims & Hers' new weight loss medication is illegal and calling it an "unapproved, inauthentic and untested knockoff semaglutide pill." "The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety

Quick answer: In head-to-head trials, tirzepatide (a dual GLP-1/GIP receptor agonist) produced greater weight loss than semaglutide (a single GLP-1 agonist) 20.2% vs 13.7% over 72 weeks in SURMOUNT-5 though semaglutides single-pathway selectivity keeps it valuable in research

Take the injection at the same time each week to maintain consistent blood levels

Please try again According to the Canadian Patent Database, Novo Nordisk was first issued the patent in 2013 but it is now expired and beyond the period of reversal. A report by Science said the pharma company last paid the annual maintenance fee on 2018, which at the time was $250